SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026GuruFocus · Oct 17, 2026
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseaseGuruFocus · Oct 11, 2026
Brookfield Real Assets Income Fund Inc. (NYSE:RA) Shareholders Set to Receive $0.12 Monthly DividendDefense World · Oct 7, 2026
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressGuruFocus · Sep 30, 2026
Brookfield Real Assets Income Fund (NYSE:RA) Stock Sale Disclosed by Rep. Kevin HernDefense World · Sep 29, 2026
Brookfield Real Assets Income Fund Inc. Declares Q4 2026 Distribution ScheduleGlobeNewsWire · Sep 25, 2026Brookfield Real Assets Income Fund Inc. is a closed ended fixed income mutual fund launched and managed by Brookfield Investment Management Inc. The fund is co-managed by Schroder Investment Management North America Inc. It invests in fixed income markets of the United States.